| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents.
|
Circulation
|
2007
|
4.71
|
|
2
|
Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases.
|
Circulation
|
2003
|
3.01
|
|
3
|
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
|
N Engl J Med
|
2007
|
2.91
|
|
4
|
Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden.
|
J Am Coll Cardiol
|
2007
|
2.50
|
|
5
|
Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.
|
Circulation
|
2003
|
2.31
|
|
6
|
Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
|
Circulation
|
2012
|
2.17
|
|
7
|
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.
|
J Am Coll Cardiol
|
2008
|
1.84
|
|
8
|
Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
|
JACC Cardiovasc Interv
|
2009
|
1.53
|
|
9
|
A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial.
|
EuroIntervention
|
2006
|
1.46
|
|
10
|
Short- and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock.
|
Cardiology
|
2012
|
1.46
|
|
11
|
The efficacy of sirolimus-eluting stents versus bare metal stents for diabetic patients undergoing elective percutaneous coronary intervention.
|
J Invasive Cardiol
|
2005
|
1.42
|
|
12
|
Three-year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus-eluting stents: insights from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital-(RESEARCH) registry.
|
Catheter Cardiovasc Interv
|
2007
|
1.40
|
|
13
|
Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
|
J Invasive Cardiol
|
2011
|
1.39
|
|
14
|
Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.14
|
|
15
|
Single-vessel or multivessel PCI in patients with multivessel disease presenting with non-ST-elevation acute coronary syndromes.
|
EuroIntervention
|
2013
|
1.09
|
|
16
|
Fatigue, depressive symptoms, and hopelessness as predictors of adverse clinical events following percutaneous coronary intervention with paclitaxel-eluting stents.
|
J Psychosom Res
|
2007
|
1.02
|
|
17
|
The future of drug-eluting stents.
|
Pharmacol Res
|
2008
|
1.01
|
|
18
|
Three-year follow-up of the ARTS-II# - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.
|
EuroIntervention
|
2008
|
0.98
|
|
19
|
Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions.
|
Neth Heart J
|
2015
|
0.98
|
|
20
|
Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: a Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry substudy.
|
J Am Coll Cardiol
|
2004
|
0.97
|
|
21
|
Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry.
|
Circulation
|
2007
|
0.95
|
|
22
|
The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
|
JACC Cardiovasc Interv
|
2009
|
0.94
|
|
23
|
Very long sirolimus-eluting stent implantation for de novo coronary lesions.
|
Am J Cardiol
|
2004
|
0.92
|
|
24
|
The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease.
|
Eur Heart J
|
2005
|
0.92
|
|
25
|
Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: insight into the RESEARCH and T-SEARCH registries.
|
Catheter Cardiovasc Interv
|
2007
|
0.90
|
|
26
|
Chronic total occlusion treatment in post-CABG patients: saphenous vein graft versus native vessel recanalization-long-term follow-up in the drug-eluting stent era.
|
Catheter Cardiovasc Interv
|
2007
|
0.89
|
|
27
|
Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents.
|
Am J Cardiol
|
2005
|
0.85
|
|
28
|
Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.
|
Clin Cardiol
|
2012
|
0.85
|
|
29
|
Short- and long-term outcomes in octogenarians undergoing percutaneous coronary intervention with stenting.
|
EuroIntervention
|
2012
|
0.84
|
|
30
|
Virtual histology and remodelling index allow in vivo identification of allegedly high-risk coronary plaques in patients with acute coronary syndromes: a three vessel intravascular ultrasound radiofrequency data analysis.
|
EuroIntervention
|
2006
|
0.83
|
|
31
|
Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease.
|
EuroIntervention
|
2010
|
0.81
|
|
32
|
Primary percutaneous coronary intervention for acute myocardial infarction: long-term outcome after bare metal and drug-eluting stent implantation.
|
Circ Cardiovasc Interv
|
2008
|
0.81
|
|
33
|
Contemporary treatment of patients with chronic total occlusion: critical appraisal of different state-of-the-art techniques and devices.
|
EuroIntervention
|
2007
|
0.81
|
|
34
|
Type-D personality exerts a stable, adverse effect on vital exhaustion in PCI patients treated with paclitaxel-eluting stents.
|
J Psychosom Res
|
2007
|
0.81
|
|
35
|
Rapid exchange ultra-thin microcatheter using fibre-optic sensing technology for measurement of intracoronary fractional flow reserve.
|
EuroIntervention
|
2015
|
0.81
|
|
36
|
Rheolytic thrombectomy in patients with ST-elevation myocardial infarction and large thrombus burden: the Thoraxcenter experience.
|
J Invasive Cardiol
|
2006
|
0.80
|
|
37
|
Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts.
|
EuroIntervention
|
2008
|
0.80
|
|
38
|
Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
|
Eur Heart J
|
2006
|
0.80
|
|
39
|
Three-year survival following multivessel percutaneous coronary intervention with bare-metal or drug-eluting stents in unselected patients.
|
Am J Cardiol
|
2008
|
0.79
|
|
40
|
Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study.
|
EuroIntervention
|
2012
|
0.79
|
|
41
|
High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention.
|
EuroIntervention
|
2016
|
0.78
|
|
42
|
Impact of body mass index on the one-year clinical outcome of patients undergoing multivessel revascularization with sirolimus-eluting stents (from the Arterial Revascularization Therapies Study Part II).
|
Am J Cardiol
|
2008
|
0.78
|
|
43
|
Feelings of being disabled as a prognostic factor for mortality in the drug-eluting stent era.
|
J Psychosom Res
|
2009
|
0.78
|
|
44
|
Short- and long- term health related quality-of-life and anginal status after randomisation to coronary stenting versus bypass surgery for the treatment of multivessel disease: results of the Arterial Revascularisation Therapy Study (ARTS).
|
EuroIntervention
|
2008
|
0.77
|
|
45
|
Current technologies: an introduction.
|
EuroIntervention
|
2013
|
0.77
|
|
46
|
Comparison of long-term outcomes in STEMI and NSTE-ACS after coronary stent placement: an analysis in a real world BMS and DES population.
|
Int J Cardiol
|
2012
|
0.76
|
|
47
|
Update on stents: recent studies on the TAXUS stent system in small vessels.
|
Vasc Health Risk Manag
|
2007
|
0.76
|
|
48
|
Drug-eluting stents vs. coronary-artery bypass grafting.
|
N Engl J Med
|
2008
|
0.76
|
|
49
|
Drug-eluting stents, restenosis and revascularization.
|
Herz
|
2007
|
0.76
|
|
50
|
Drug-eluting stent implantation in acute myocardial infarction. Do we need another randomised trial? (TYPHOON, PASSION and HORIZONS trials).
|
EuroIntervention
|
2006
|
0.75
|
|
51
|
Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study.
|
EuroIntervention
|
2016
|
0.75
|
|
52
|
Serial quantitative magnetic resonance angiography follow-up of renal artery dimensions following treatment by four different renal denervation systems.
|
EuroIntervention
|
2017
|
0.75
|
|
53
|
Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention.
|
EuroIntervention
|
2017
|
0.75
|
|
54
|
Polarimetric Signatures of Vascular Tissue Response to Drug-Eluting Stent Implantation in Patients.
|
JACC Cardiovasc Imaging
|
2020
|
0.75
|
|
55
|
The use of drug-eluting stents in ST-elevation myocardial infarction.
|
EuroIntervention
|
2009
|
0.75
|
|
56
|
The PulseCath iVAC 2L left ventricular assist device: conversion to a percutaneous transfemoral approach.
|
EuroIntervention
|
2015
|
0.75
|
|
57
|
Effectiveness of sirolimus-Eluting stent implantation for coronary narrowings <50% in diameter.
|
Am J Cardiol
|
2004
|
0.75
|
|
58
|
Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial.
|
EuroIntervention
|
2016
|
0.75
|
|
59
|
Design and Principle of Operation of the HeartMate PHPTM (Percutaneous Heart Pump).
|
EuroIntervention
|
2016
|
0.75
|
|
60
|
First-in-man six-month results of a surface-modified coronary stent system in native coronary stenosis.
|
EuroIntervention
|
2017
|
0.75
|
|
61
|
Single-access balloon aortic valvuloplasty - an overview of contemporary technical improvements.
|
EuroIntervention
|
2019
|
0.75
|
|
62
|
Three-year clinical event rates in different age groups after contemporary percutaneous coronary intervention.
|
EuroIntervention
|
2011
|
0.75
|
|
63
|
MANTA, a novel plug-based vascular closure device for large bore arteriotomies: technical report.
|
EuroIntervention
|
2016
|
0.75
|
|
64
|
The SCAAR registry or the Swedish yo-yo.
|
EuroIntervention
|
2007
|
0.75
|
|
65
|
Two-year outcome of the use of paclitaxel-eluting stents in aorto-ostial lesions.
|
Int J Cardiol
|
2007
|
0.75
|